VEGFA and neoplasm: Bevacizumab-VEGF inhibitor, in combination with other anti-angiogenic agents (murine inhibitor) and ONC201 in both CRC xenograft and patient-derived xenograft (PDX) models, may lead to significant tumor regression or even complete tumor ablation [169].